115 results
Page 3 of 6
POSASR
oe2js n9spj
3 Mar 22
Automatic shelf registration (post-effective amendment)
7:00am
8-K
EX-99.1
o1hjn zj0
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
8d1wvx6
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
jf8pv f3mv9t882gc6dp
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.1
m6g0 opogpngre7fy
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.2
fqzvv5i7
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
EX-99.1
ndup4g4qn2bk
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
EX-99.1
5863s87is36pst2n2q
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.2
2ew4c6 43cuekgo
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
zxkq qz7t869v
4 Oct 21
Regulation FD Disclosure
7:31am
8-K
EX-99.1
32stfpa3y9s4bsxdt
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.2
8c4sjst1
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.2
yzn7mujr2ahij2 ro9v
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
8-K
EX-99.1
6pi7u9mqi3 yrfx4
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
DEF 14A
fxbfyw5ayq112ao
14 Apr 21
Definitive proxy
4:01pm